US2022096396A1PendingUtilityA1

Treatment of autism with cannabidiol

Assignee: ZYNERBA PHARMACEUTICALS INCPriority: Sep 28, 2017Filed: Sep 2, 2021Published: Mar 31, 2022

Est. expirySep 28, 2037(~11.2 yrs left)· nominal 20-yr term from priority

Inventors:Terri Sebree Marcel Bonn-Miller Donna Gutterman

A61K 36/3482A61K 31/658A61P 25/22A61K 9/0014A61P 25/18A61K 9/06A61P 25/00A61K 36/185A61K 31/05

PatentIndex Score

Cited by

References

Claims

Abstract

The present technology relates to a method of treating one or more behavioral symptoms of Autism Spectrum Disorder (ASD) in a subject by transdermally administering an effective amount of cannabidiol (CBD) to the subject wherein one or more behavioral symptoms of ASD are treated in the subject.

Claims

exact text as granted — not AI-modified

1 - 30 . (canceled) 
     
     
         31 . A method of treating a human suffering from an autism spectrum disorder comprising:
 transdermally administering via a gel or cream a therapeutically effective amount of purified cannabidiol to the human suffering from the autism spectrum disorder to effectively treat the autism spectrum disorder in the human in need thereof.

Join the waitlist — get patent alerts

Track US2022096396A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.